

Retraction: MicroRNA98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4

Wuyuan Zhou¹, Benkui Zou², Lisheng Liu³, Kai Cui¹, Jie Gao¹, Shuanghu Yuan⁴ and Ning Cong⁵

¹Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China

²Department of Urology Surgery, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China

³Clinical Laboratory, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China

⁴Department of Radiation Oncology, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China

⁵Department of Intervention Therapy, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China

Published: May 20, 2026

Copyright: © 2026 Zhou et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: This decision follows an investigation by Oncotarget Scientific Integrity office, that revealed multiple image duplications across several figures, involving unrelated articles published before, concurrently, or after the submission. Specifically:

- Transwell Assay Images: Images in Figure 3C, 3D were found in reference [1] (Figure 3B and Figure 6B), [2] (Figure 4C), [3] (Figure 6), [4] (Figure 3C, 3D), and [5–6] (Figure 2C and Figure 4C). Additionally, Figure 2D and Figure 4C of [7] and Figure 4B of [8] contain these duplicates. Images from Figure 7C, 7D were also found in a 2015 article [9] and 2016 articles [4–6, 10].
- Wound Healing Assay Images: Images in Figures 3A, 3B, 7A, and 7B were found in a 2015 article [11] (Figure 4), [12] (Figures 4D and 5C), and in later publications.
- Western Blot Images:
 - Figure 4A blots match reference [13] (Figure 2B) and [8] (Figure 4I).
 - Figure 4B (MMP2) matches a 2013 article [14] (Figure 4B as Bax/CHG), a 2015 article [9] (Figure 5B as Robo1), [15] (Figure 4D), and [8] (Figure 4I).
 - Figure 4C, 4D blots are duplicated in [16] (Figure 3E), [8] (Figures 3H and 4A), and [15] (Figure 2C).
 - Figure 5F (Src) is a duplicate of a 2013 article [14] (Figure 6).
 - Figure 8A–8C were found in a 2016 paper [16] (Figures 1C and 6E).
- Tumor Images: Figure 10C images are identical to a 2015 article [17] (Figure 7C).

As the authors have not responded to previous multiple requests for comment or provided the original data, the journal is proceeding with the retraction. While we have attempted to reach all co-authors regarding this matter, none of the authors could be reached.

Original article: Oncotarget. 2016; 7:74059–74073. <https://doi.org/10.18632/oncotarget.12190>

REFERENCES

1. Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y, Yin G, Wen J. MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1. *Oncol Rep.* 2015; 34:399–406. <https://doi.org/10.3892/or.2015.3986>. [PubMed]. Retraction in: *Oncol Rep.* 2021; 46:147. <https://doi.org/10.3892/or.2021.8098>. [PubMed]
2. Lai C, Chen Z, Li R. MicroRNA-133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin-bundling protein 1. *Mol Med Rep.* 2015; 12:1473–78. <https://doi.org/10.3892/mmr.2015.3545>. [PubMed]. Retraction in: *Mol Med Rep.* 2021; 24:546. <https://doi.org/10.3892/mmr.2021.12185>. [PubMed]
3. Deng G, Zhu L, Huang F, Nie W, Huang W, Xu H, Zheng S, Yi Z, Wan T. SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma. *Oncotarget.* 2015; 6:27416–26. <https://doi.org/10.18632/oncotarget.4862>. [PubMed]

4. Zhang C, Long F, Wan J, Hu Y, He H. MicroRNA-205 acts as a tumor suppressor in osteosarcoma via targeting RUNX2. *Oncol Rep.* 2016; 35:3275–84. <https://doi.org/10.3892/or.2016.4700>. [PubMed]. Retraction in: *Oncol Rep.* 2021; 46:155. <https://doi.org/10.3892/or.2021.8106>. [PubMed]
5. Xiao L, Zhou H, Li XP, Chen J, Fang C, Mao CX, Cui JJ, Zhang W, Zhou HH, Yin JY, Liu ZQ. MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1. *Oncotarget.* 2016; 7:40038–46. <https://doi.org/10.18632/oncotarget.9480>. [PubMed]. Retraction in: *Oncotarget.* 2024; 15:590. <https://doi.org/10.18632/oncotarget.28645>. [PubMed]
6. Tian Q, Xiao Y, Wu Y, Liu Y, Song Z, Gao W, Zhang J, Yang J, Zhang Y, Guo T, Dai F, Sun Z. MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression. *Int J Mol Med.* 2016; 38:1587–95. <https://doi.org/10.3892/ijmm.2016.2754>. [PubMed]. Retraction in: *Int J Mol Med.* 2021; 48:170. <https://doi.org/10.3892/ijmm.2021.5003>. [PubMed]
7. Liu Z, Wang J, Mao Y, Zou B, Fan X. MicroRNA-101 suppresses migration and invasion via targeting vascular endothelial growth factor-C in hepatocellular carcinoma cells. *Oncol Lett.* 2016; 11:433–38. <https://doi.org/10.3892/ol.2015.3832>. [PubMed]
8. Zhou Y, Liu Y, Hu C, Jiang Y. MicroRNA-16 inhibits the proliferation, migration and invasion of glioma cells by targeting Sal-like protein 4. *Int J Mol Med.* 2016; 38:1768–76. <https://doi.org/10.3892/ijmm.2016.2775>. [PubMed]
9. Liu X, Cai J, Sun Y, Gong R, Sun D, Zhong X, Jiang S, He X, Bao E, Yang L, Li Y. MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells. *Mol Med Rep.* 2015; 12:3944–50. <https://doi.org/10.3892/mmr.2015.3817>. [PubMed]
10. Zhu L, Huang F, Deng G, Nie W, Huang W, Xu H, Zheng S, Yi Z, Wan T. Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells. *Onco Targets Ther.* 2016; 9:5297–305. <https://doi.org/10.2147/OTT.S107214>. [PubMed]
11. Cao J, Liu J, Xu R, Zhu X, Liu L, Zhao X. MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells. *Mol Med Rep.* 2016; 13:75–82. <https://doi.org/10.3892/mmr.2015.4568>. [PubMed]
12. Su F, Chen Y, Zhu S, Li F, Zhao S, Wu L, Chen X, Su J. RAB22A overexpression promotes the tumor growth of melanoma. *Oncotarget.* 2016; 7:71744–53. <https://doi.org/10.18632/oncotarget.12329>. [PubMed]. Retraction in: *Oncotarget.* 2025; 16:347. <https://doi.org/10.18632/oncotarget.28726>. [PubMed]
13. Deng G, Teng Y, Huang F, Nie W, Zhu L, Huang W, Xu H. MicroRNA-101 inhibits the migration and invasion of intrahepatic cholangiocarcinoma cells via direct suppression of vascular endothelial growth factor-C. *Mol Med Rep.* 2015; 12:7079–85. <https://doi.org/10.3892/mmr.2015.4239>. [PubMed]
14. Peng R, Jiang B, Ma J, Ma Z, Wan X, Liu H, Chen Z, Cheng Q, Chen R. Forced downregulation of RACK1 inhibits glioma development by suppressing Src/Akt signaling activity. *Oncol Rep.* 2013; 30:2195–202. <https://doi.org/10.3892/or.2013.2723>. [PubMed]
15. Chen Y, Cao KE, Wang S, Chen J, He B, He GU, Chen Y, Peng B, Zhou J. MicroRNA-138 suppresses proliferation, invasion and glycolysis in malignant melanoma cells by targeting HIF-1 α . *Exp Ther Med.* 2016; 11:2513–18. <https://doi.org/10.3892/etm.2016.3220>. [PubMed]. Retraction in: *Exp Ther Med.* 2023; 27:65. <https://doi.org/10.3892/etm.2023.12353>. [PubMed]
16. Wang Y, Ouyang M, Wang Q, Jian Z. MicroRNA-142-3p inhibits hypoxia/reoxygenation-induced apoptosis and fibrosis of cardiomyocytes by targeting high mobility group box 1. *Int J Mol Med.* 2016; 38:1377–86. <https://doi.org/10.3892/ijmm.2016.2756>. [PubMed]
17. Li J, Yuan J, Yuan X, Zhao J, Zhang Z, Weng L, Liu J. MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2. *Int J Oncol.* 2016; 48:541–50. <https://doi.org/10.3892/ijo.2015.3267>. [PubMed]. Retraction in: *Int J Oncol.* 2021; 59:65. <https://doi.org/10.3892/ijo.2021.5245>. [PubMed]